OXB (formerly Oxford BioMedica), a listed gene and cell therapy firm, is anticipating strong growth in its latest half-year trading update.

Discover a study exploring cutting-edge melanoma vaccines and their potential to enhance long-term survival in high-risk patients.

In this context, cooperation with Türkiye has taken on a systematic and long-term character, covering the economy, defense, ...

The Pennsylvania Department of Environmental Protection Vector Management has reported to the Centre County Planning and Community Development Office that one mosquito sample collected recently in Che ...

Oxford Biomedica reported a sharp rise in first-half revenue and strong commercial momentum on Monday, as it reiterated its ...

Explore Iberdrola & Echelon's venture for clean-energy-powered data centres across Spain, meeting digital infrastructure ...

Java defies the hype cycle, thriving at 30 with unmatched enterprise trust, modern AI integration, and a vibrant, global ...

The Oxford, England-based cell and gene therapy contract development and manufacturing company said it expects to report revenue between GBP70 million and GBP73 million for the six months to the end ...

Cash Position: GeoVax reported cash balances of $3,093,862 at June 30, 2025, as compared to $5,506,941 at December 31, 2024. During July 2025, the Company completed a public offering of common stock ...

In the 1st half of 2025, revenue from all DOLFINES activities was €4.19 millions, down 14% compared to the 1st half of 2024. Excluding the Audit activities of 8.2 Advisory, which were sold on June 1, ...

With a strong foundation of technical progress and expanding geological potential across the 57 km² Ishkōday land package, LAURION is well-positioned for continued strategic interest. Shareholders are ...

Agrawal felt a calling for higher service and signed up to join the Air Force. Given his background in music, he initially ...